Alnylam Pharmaceuticals CEO: Trial results open up the doors for a new class of medicines

2:37 PM ET Thu, 21 Sept 2017

Alnylam Pharmaceuticals CEO John Maraganore discusses his company's successful drug trial to treat a rare nerve disorder, and what he sees for the underlying technology. With CNBC's Meg Tirrell.